Alka Shrikhande - Concepedia

Concepedia

Author

Alka Shrikhande

Pfizer (United States)

Also Known As

A Shrikhande, A V Shrikhande, A. Shrikhande, A. V. Shrikhande, A.V. SHRIKHANDE, A.V. Shrikhande, Alka Shrikhande, Alka V. Shrikhande, Anitha Shrikhande, Anuja Shrikhande

48

Publications

2.1K

Citations

15

H-Index

70

Concepts

All Affiliations

Pfizer (United States)Bayer (United States)Bayer (Germany)Government Medical College Indira Gandhi Medical College

AS

About

Alka Shrikhande is an author at Pfizer (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	830
2	Social Sciences	3	3	374
3	Biochemistry	3	3	47
4	Health Sciences	1	1	14
5	Natural Sciences	1	1	132

Alka Shrikhande

×

22

Publications

2.1K

Citations

15

H-Index

	Year	Citations
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino, Journal of Medicinal Chemistry	2005	929
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis Judith A. Siuciak, Douglas S. Chapin, John F. Harms, Neuropharmacology NeuropsychologyPsychiatryPsychotic DisorderPsychotropic MedicationNovel Approach	2006	274
Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence Hans Rollema, Alka Shrikhande, KM Ward, British Journal of Pharmacology	2010	162
<i>N</i>-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage Pat Loulakis, Alka Shrikhande, Gary L. Davis, Biochemical Journal Tissue EngineeringIl-1-treated CulturesImmunologyPathologyMusculoskeletal Research	1992	132
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect Hans Rollema, Victor Guanowsky, Yann S. Mineur, European Journal of Pharmacology Antidepressant-like ActivityPsychiatryMedicineDepressionPsychopharmacology	2009	85
Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk, Journal of Medicinal Chemistry	2009	73
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors Jacques Dumas, Holia Hatoum‐Mokdad, Robert Sibley, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal Chemistry1-Phenyl-5-pyrazolyl UreasMedicinePharmacological Agent	2000	53
Discovery of a new class of p38 kinase inhibitors Jacques Dumas, Robert Sibley, Bernd Riedl, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetP38 Kinase InhibitorsMedicineRational Drug Design	2000	47
p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas Anikó M. Redman, Jeffrey S. Johnson, Robert Dally, Bioorganic & Medicinal Chemistry Letters Pharmaceutical ChemistryP38 Kinase InhibitorsMedicineOsteoarthritisPharmacological Agent	2001	44
Cartilage chondrolysis by fibronectin fragments causes cleavage of aggrecan at the same site as found in osteoarthritic cartilage Gene A. Homandberg, Gary L. Davis, Charles A. Maniglia, Osteoarthritis and Cartilage MechanobiologyMusculoskeletal ResearchBone Morphogenic ProteinConnective Tissue DiseaseMedicine	1997	42

Page 1